Real-world effectiveness studies of the benefit of RSV vaccines
- PMID: 39426823
- DOI: 10.1016/S0140-6736(24)02150-0
Real-world effectiveness studies of the benefit of RSV vaccines
Conflict of interest statement
ARB reports grant funding to their institution from Pfizer, Moderna, Merck, Cyanvac, and Vaccitech; serves as a consultant for GSK, Moderna, Sanofi, and Merck; and reports support for attending meetings and honoraria for presentations from Sanofi.
Comment on
-
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.Lancet. 2024 Oct 19;404(10462):1547-1559. doi: 10.1016/S0140-6736(24)01738-0. Lancet. 2024. PMID: 39426837
Publication types
LinkOut - more resources
Full Text Sources
